What the hip experience explores
Professor Lee reports experience with Arthrosamid in 150 hips, with follow-up extending to 3 years. This clinical series creates an opportunity to discuss how assessment, injection technique and follow-up differ when treating a joint other than the knee.
The figures come from Professor Lee’s clinical brief. A joint-specific publication and complete follow-up dataset have not yet been supplied, so no response percentage is presented here.
Why hip assessment matters
Hip-region pain is not always generated by the hip joint. Groin symptoms, lateral hip pain and referred pain may need different assessment and treatment pathways. An injection discussion should start with identifying the source.
Questions to discuss include whether the symptoms come from the joint, how advanced the structural changes are, and when a replacement opinion would be more useful. The reported number treated cannot answer these questions for an individual patient.
Make the outcome relevant to daily life
For someone with hip symptoms, useful goals might include walking comfortably, getting in and out of a car or putting on shoes. Recording the starting point and reviewing the same activities later makes a clinical conversation more specific.
Follow-up should also record unwanted effects, any further treatment and how many people were assessed at each time point. A series followed for several years does not mean every patient has reached its longest follow-up.
Where this sits in the research
The current manufacturer instructions cover symptomatic knee osteoarthritis and advise against injection into other body parts. The experience discussed here is outside that indication; knee results cannot establish effectiveness or safety in this joint.
A developing area for clinical discussion
A separate Southampton-led observational study, ISRCTN15283289, has been registered to examine polyacrylamide hydrogel in synovial joints. It has no published results and is not Professor Lee’s reported series. It shows that the wider research question is being studied, rather than supplying outcomes for the cases discussed here.
Clinicians can use the AMSK masterclass or a clinical visit to explore the case-selection questions with Professor Lee. For patients, an individual specialist assessment is the place to discuss established options and the uncertainties around any proposed use.
Sources and further reading
- Professor Lee: joint injections and clinical experience
- Arthrosamid instructions for use, October 2025
- ISRCTN15283289: planned synovial-joint study, no results yet
General information to support a clinical conversation. AMSK and Professor Lee are part of the MSK Doctors group; group publications are identified above.
Editorial review notes · Preview only
Obtain de-identified hip series, dates, follow-up completeness, outcomes, adverse events and publication status. Counts attributed to Paul’s supplied brief only.